Mankind Pharma Limited
NSE: MANKIND · Pharmaceuticals · sector
₹2,312.00NSE close 2026-10-26
Key numbers
Market cap₹95,486 cr
Price₹2,312.00
52w high / low₹2,642 / ₹1,910
P/E46.7xSector median 27.9x
P/B5.9xSector median 2.9x
Book value₹394.7
Dividend yield0.04%Sector median 0.48%
ROE13.4%Sector median 11.7%
ROCE13.8%Sector median 12.3%
OPM25.1%Sector median 14.0%
Debt / equity0.39xSector median 0.16x
EV/EBITDA27.0xSector median 18.6x
Interest cover5.4x
Current ratio1.10x
Sales growth 3y+17.7%Sector median +9.6%
Profit growth 3y+14.3%Sector median +13.3%
PEG3.55x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2,020 cr vs borrowings ₹6,312 cr (FY26): borrowings are higher by ₹4,291 cr.
- Operating profit covered interest 5.4x in the last 12 months.
- Operating cash flow was below net profit in 0 of the last 4 years.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 16% of net profit in the last 12 months.
- Debtor days went from 30 (FY24) to 44 (FY26).
- Dividend paid in 1 of the last 4 financial years.
- Price ₹2,312.00 on 2026-10-26: -12.5% from the 52-week high, +21.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,937.55 · low ₹1,927.40
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,077 | 3,230 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 |
| EBITDA | 850 | 830 | 683 | 847 | 921 | 813 | 907 | 1,056 |
| OPM % | 27.6% | 25.7% | 22.2% | 23.7% | 24.9% | 22.8% | 26.3% | 26.2% |
| Other income | 109 | 77 | 251 | 80 | 92 | 73 | 114 | 45 |
| Net profit | 653 | 380 | 425 | 438 | 512 | 409 | 554 | 574 |
| EPS (₹) | 16.31 | 9.45 | 10.19 | 10.62 | 12.39 | 9.90 | 13.44 | 13.76 |
| Revenue YoY | +20.2% | +10.4% | +11.8% | +12.9% | ||||
| Profit YoY | -21.7% | +7.5% | +30.4% | +31.0% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 8,749 | 10,335 | 12,207 | 14,278 | 14,738 |
| EBITDA | 1,901 | 2,535 | 3,018 | 3,488 | 3,697 |
| Net profit | 1,282 | 1,913 | 1,986 | 1,913 | 2,049 |
| EPS (₹) | 32.00 | 47.75 | 49.28 | 46.35 | 49.49 |
| Revenue growth | +18.1% | +18.1% | +17.0% | +13.8% | |
| Profit growth | +49.2% | +3.8% | -3.7% | +8.0% | |
| Dividend / share (₹) | – | – | – | 1.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +17.7% | – | +13.8% |
| Net profit | +14.3% | – | +8.0% |
| EPS | +13.1% | – | – |
| Share price | – | -7.1% (2y) | -6.5% |
Balance sheet
| ₹ cr | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Shareholders' equity | 7,435 | 9,363 | 14,332 | 16,300 |
| Borrowings | 170 | 207 | 8,511 | 6,312 |
| Cash & equivalents | 1,529 | 3,456 | 2,245 | 2,020 |
| Total assets | 9,715 | 11,963 | 27,760 | 28,080 |
| Fixed assets | 2,524 | 2,932 | 2,908 | 2,960 |
| Capital work in progress | 493 | 207 | 306 | 655 |
| Investments | 271 | 310 | 160 | 248 |
| Receivables | 576 | 848 | 1,538 | 1,730 |
| Inventory | 1,498 | 1,553 | 2,094 | 2,144 |
| Payables | 1,008 | 1,103 | 1,133 | 1,341 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Cash from operations | 1,813 | 2,152 | 2,413 | 3,121 |
| Cash from investing | -1,054 | -2,082 | -12,683 | -196 |
| Cash from financing | -740 | 5 | 10,290 | -2,953 |
| Capex | 832 | 382 | 520 | 737 |
| Free cash flow | 981 | 1,770 | 1,893 | 2,384 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ROE % | 17.2% | 20.4% | 13.9% | 11.7% |
| ROCE % | 22.4% | 25.3% | 12.8% | 13.1% |
| Debtor days | 24 | 30 | 46 | 44 |
| Inventory days | 188 | 177 | 219 | 193 |
| Payable days | 126 | 125 | 119 | 121 |
| Cash conversion cycle (days) | 86 | 82 | 146 | 116 |
| Working capital days | 107 | 160 | 45 | 16 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 72.62% |
| FIIs | 9.37% |
| DIIs | 15.56% |
| of which Mutual funds | 11.31% |
| of which Insurance | 1.37% |
| Public (non-institutions) | 2.45% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 72.71% | 72.70% | 72.68% | 72.67% | 72.66% | 72.66% | 72.63% | 72.62% |
| Promoter group | % |
|---|---|
| Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee) | 20.18% |
| Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee) | 19.35% |
| Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee) | 14.95% |
| Sheetal Arora | 4.67% |
| Puja Juneja | 2.79% |
| Poonam Juneja | 2.56% |
| Arjun Juneja | 1.97% |
| Ramesh Juneja | 1.66% |
| Rajeev Juneja | 1.57% |
| Eklavya Juneja | 0.94% |
| Chanakya Juneja | 0.94% |
| Mishka Arora | 0.72% |
| RIA Chopra Juneja | 0.31% |
| Ayushi Juneja Sikri | 0.00% |
| Pushpa Rani Aggarwal | 0.00% |
| Public holders above 1% | % |
|---|---|
| NPS Trust- A/C LIC Pension Fund Scheme - State GOV | 2.65% |
| Nippon Life India Trustee Ltd-a/c Nippon India RET | 2.45% |
| SBI ESG Exclusionary Strategy Fund | 1.49% |
| Aditya Birla SUN Life Mutual Fund - Aditya Birla S | 1.21% |
| Government Pension Fund Global | 1.06% |
1,63,770 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| LUPIN | ₹89,616 cr | 16.2x | 4.0x | 27.9% | 27.9% | 30.0% | +18.9% | 0.61% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2025-08-08 | Dividend | Interim Dividend - Re 1 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Trading: Wholesale trading
- Manufacturing: Chemicals & chemical products, pharmaceuticals, medicinal & botanical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MANKIND |
| BSE code | 543904 |
| ISIN | INE634S01028 |
| Face value | ₹1.0 |
| Incorporated | 1991-07-03 |
| Website | https://www.mankindpharma.com |
| Plants (India / abroad) | 7 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.